Researchers Compared DNA Assay Methods for Lung Cancer

A study at Northwestern University evaluated tumor-informed and tissue-agnostic methods for tracking disease progression.

Updated on Oct. 8, 2026 in Cancer

Researchers Compared DNA Assay Methods for Lung Cancer

Live Poll

Would you prefer using multiple diagnostic testing approaches for cancer surveillance rather than just one?

Researchers have compared tumor-informed and tissue-agnostic ctDNA assays to improve surveillance for patients recovering from lung cancer. Each method effectively detects molecular residual disease, with the two approaches capturing different cases.

Why it matters

The findings help clinicians effectively monitor lung cancer recurrence when surgical tissue samples are depleted or otherwise unavailable for testing. Using these methods in tandem provides a more robust surveillance strategy for post-surgical care.

Tumor-informed assays require tissue biomarkers and are performed every 3 months for clinical surveillance. Tissue-agnostic assays operate without tumor tissue, utilizing plasma-only analysis to identify shed DNA.

The players

Young Kwang Chae

He is the lead researcher at Northwestern University who conducted the comparative study on lung cancer surveillance assays.

Northwestern University

This is the academic and clinical institution where the comparative research on ctDNA lung cancer surveillance was performed.

The details

Tumor-informed assays are built using specific markers derived from surgery or biopsy samples, while tissue-agnostic assays compare plasma cell-free DNA against germline and library data. Because immunohistochemistry workups often deplete limited tissue samples, the two methods are used together to ensure no molecular indicators are missed.

Blood-based tumor-informed surveillance assays are performed every 3 months.

The Big Picture

This study at the Northwestern University liquid biopsy research program extends established protocols for monitoring patient response to treatment. By validating the use of multiple assay types, the research shifts the standard of care toward more flexible molecular surveillance.

Patients may benefit from more accurate recurrence monitoring, even when initial surgical tissue samples were insufficient for traditional testing. This dual-method approach can provide earlier detection of molecular residual disease during routine post-surgical checkups.

The takeaway

Using both tumor-informed and tissue-agnostic assays offers a more reliable safety net for patients undergoing lung cancer surveillance. Patients should discuss with their oncology team which surveillance frequency and diagnostic methods are most appropriate for their specific history.